An administrative legislation decide has dominated in favor of Illumina in its $7.1 billion acquisition of cancer-testing developer Grail Inc., dealing a defeat to the Federal Commerce Fee’s efforts to unwind the deal on antitrust grounds, the corporate stated.
Illumina stated the decide rejected the FTC’s place that the deal would harm competitors out there for multicancer early-detection assessments.
